Spero Therap
SPRO1.1800.84% ( -0.010 )
Spero Therap (SPRO)
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bact...
- Open
- 1.200
- High
- 1.230
- Low
- 1.160
- Prev. Close
- 1.190
- Volume
- 1.35M
- Turnover
- 1.61M
- Avg Price
- 1.192
- Bid/Ask Ratio
- --
- Amplitude
- 5.88%
- 52wk High
- 3.080
- Volume Ratio
- 0.31
- Turnover Ratio
- 2.90%
Spero Therap Analyst Rating
View MoreForecast & Rating
Jun 18, 2026Price forecast
$4.00238.98%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 14 hours ago
Spero Therapeutics appoints Debra Jeske Zack as chief medical officer
- AASTOCKS News · Jul 15 at 11:36 PM
CLSA Raises INNOVENT BIO TP to HKD139.9, Secures Another Partnership Deal
- Pharmaceutical Technology · Jul 15 at 04:01 AM
Innovent licenses IBI355 rights to Spero for up to $1.1bn
- Tip Ranks · Jul 15 at 03:11 AM
Spero Therapeutics inks major CD40L and royalty deals
- PR Newswire · Jul 14 at 05:00 AM
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
- benzinga_article · Jul 14 at 12:05 PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
